(Q33330193)

25 July 2017

title

Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma (English)

1 reference

25 July 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

gastric adenocarcinoma

1 reference

Kim NK

1

1 reference

25 July 2017

Im SA

2

1 reference

25 July 2017

Kim DW

3

1 reference

25 July 2017

Lee MH

4

1 reference

25 July 2017

Jung CW

5

1 reference

25 July 2017

Cho EK

6

1 reference

25 July 2017

Lee JT

7

1 reference

25 July 2017

Ahn JS

8

1 reference

25 July 2017

Heo DS

9

1 reference

25 July 2017

Bang YJ

10

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

25 July 2017

1 reference

25 July 2017

volume

86

1 reference

25 July 2017

issue

7

1 reference

25 July 2017

page(s)

1109-1115

1 reference

Current status of chemotherapy for gastric cancer

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Preclinical antitumor and toxicologic profile of carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Cisplatin/carboplatin cross-resistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Influence of exposure and infusion times on the cytotoxicity and pharmacokinetics of cis-malonato[(4R, 5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) .

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Cis-platinum as second-line chemotherapy in advanced gastric adenocarcinoma. A phase II study of the EORTC gastrointestinal tract cancer cooperative group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Preclinical studies identifying carboplatin as a viable cisplatin alternative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

Pharmacokinetics and antitumor activity of a new platinum compound, cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1, 3- dioxolane]platinum(II), as determined by ex vivo pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991001%2986%3A7%3C1109%3A%3AAID-CNCR3%3E3.0.CO%3B2-G

10.1002/(SICI)1097-0142(19991001)86:7<1109::AID-CNCR3>3.0.CO;2-G

21 January 2018

Identifiers

DOI

1 reference

25 July 2017

1 reference